TNK treatment for stroke when blood flow didn’t reopen enough
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had an acute ischemic stroke (blocked blood vessel) in the front part of the brain, and underwent a clot-removal procedure (mechanical thrombectomy).
- After the procedure, blood flow was still not good enough (mTICI 1/2a).
- You can provide consent (or your legal representative can).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-busting drug called tenecteplase given directly into the brain bleed through a thin tube. It may help reduce damage and improve recovery for people with a certain type of brain hemorrhage.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.